Author

Stanley A. Schwartz

University at Buffalo, State University of New YorkORCID 0000-0002-8664-1380Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Bioinformatics· 1 Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Organism:human· 2 Approach:experimental assay· 1 Assay:proteomics· 1 Approach:statistical model· 1

Frequent Co-Authors

Ravikumar AalinkeeliD· 2 shared Supriya D. MahajaniD· 2 shared Andrey N. KuzminiD· 1 shared Artem PlissiD· 1 shared Jun XiaiD· 1 shared Liana Bruggemann· 1 shared Mehrgan GhazaeianiD· 1 shared Mykhaylo Dukh· 1 shared

Activity by Year

2023-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 38 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Ravikumar AalinkeelORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Comparative Study of Photodynamic and Sonodynamic Therapy Using a PSMA-Targeted Up-conversion Nanoplatform for Castration-Resistant Prostate Cancer

Mehrgan Ghazaeian, Rahul Kumar Das, Ravindra Kumar Pandey, Supriya D. Mahajan, Mykhaylo Dukh, Yanda Cheng, Andrey N. Kuzmin, Artem Pliss, Stanley A. Schwartz, Jun Xia, Ravikumar Aalinkeel, Paras N. Prasad

This study compares NIR-PDT and SDT using a PSMA-targeted nanoplatform for castration-resistant prostate cancer, finding SDT provides superior therapeutic efficacy.

bioRxiv · May 29, 2026 · PreprintCancer Biology

MULTISCALE ANALYSIS AND VALIDATION OF EFFECTIVE DRUG COMBINATIONS TARGETING DRIVER KRAS MUTATIONS IN NON-SMALL CELL LUNG CANCER

Liana Bruggemann, Zackary Falls, William Mangione, Stanley A. Schwartz, Sebastiano Battaglia, Ravikumar Aalinkeel, Supriya D. Mahajan, Ram Samudrala

The paper validates that osimertinib synergizes with KRAS inhibitors to reduce NSCLC cell proliferation, with MAPK suppression as a key mechanism.

International Journal of Molecular Sciences · Jan 5, 2023Peer-reviewedBioinformatics